Disseminated intravascular coagulation during treatment with thalidomide. A case report.
The treatment with thalidomide is associated with an increased risk of thromboembolic events, in particular when it is combined with chemotherapy or dexamethasone. However, despite this well-documented prothrombotic effect, to our knowledge disseminated intravascular coagulation has never been reported in hematological or oncological patients treated with thalidomide. We report a case of disseminated intravascular coagulation in a patient treated with thalidomide and dexamethasone for advanced, heavily pretreated hormone-resistant prostate cancer in which a relationship with the treatment appears highly likely.
Tassinari
Davide
D
Department of Oncology, City Hospital, Rimini, Italy. dtassinari@rimini.com
Tombesi
Paola
P
Sartori
Sergio
S
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004211:Disseminated Intravascular Coagulation / Q000139:chemically induced*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects*
D020533:Angiogenesis Inhibitors; D018931:Antineoplastic Agents, Hormonal; D013792:Thalidomide; D003907:Dexamethasone